NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,427,402 | -43.5% | 82,588 | -18.1% | 0.19% | -47.3% |
| Q1 2023 | $6,063,736 | -3.7% | 100,827 | +17.4% | 0.36% | -16.1% |
| Q4 2022 | $6,296,951 | -4.6% | 85,848 | -1.2% | 0.43% | -5.7% |
| Q3 2022 | $6,603,000 | +3.0% | 86,903 | -5.8% | 0.46% | -4.6% |
| Q2 2022 | $6,410,000 | -27.6% | 92,232 | -13.7% | 0.48% | -4.6% |
| Q1 2022 | $8,857,000 | +19.7% | 106,902 | +8.5% | 0.50% | +34.3% |
| Q4 2021 | $7,398,000 | -25.9% | 98,540 | +14.7% | 0.38% | -30.8% |
| Q3 2021 | $9,981,000 | -45.2% | 85,916 | +4.6% | 0.54% | -45.9% |
| Q2 2021 | $18,212,000 | +122.8% | 82,101 | +32.8% | 1.00% | +103.4% |
| Q1 2021 | $8,173,000 | -20.8% | 61,829 | +3.7% | 0.49% | -18.1% |
| Q4 2020 | $10,316,000 | +57.6% | 59,618 | +1.4% | 0.60% | +35.9% |
| Q3 2020 | $6,544,000 | +320.8% | 58,794 | +124.2% | 0.44% | +203.4% |
| Q2 2020 | $1,555,000 | -11.9% | 26,222 | 0.0% | 0.15% | -26.3% |
| Q1 2020 | $1,766,000 | – | 26,222 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |